Related Experiment Video
Updated: Jul 9, 2026
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular
Laura Boldrini1, Silvia Gisfredi, Silvia Ursino
1Department of Surgery, Santa Chiara University Hospital, Pisa, Italy. l.boldrini@med.unipi.it
Introduction:
The discovery that somatic mutations in the epidermal growth factor receptor (EGFR) gene are associated with sensitivity to the EGFR tyrosine kinase inhibitors (TKIs) in lung adenocarcinomas, whereas Kras mutations are associated with resistance, has generated excitement among both clinicians and researchers studying non-small cell lung cancer (NSCLC). Mutational analysis may soon be very useful in choosing among a wide range of targeted therapies to individualize treatment to tumor characteristics. This analysis would be even more useful in patients with advanced NSCLC, in whom cytological specimens are often the only material available.
Methods:
We analyzed 23 archived cytologic specimens of advanced/metastatic lung adenocarcinomas for mutations in EGFR exons 18 to 21, and Kras exon 2.
Results:
Our data show that our cytological specimens were perfectly adequate for the molecular analysis of EGFR and Kras mutations. EGFR TK domain mutations were found in three cases (13.04%) and were associated with both female gender (p = 0.02) and a nonsmoking history (p = 0.008). Moreover, we explored the relationship between EGFR mutation status and the presence of Kras mutations. Kras mutations involving codon 12 in exon 2 were found in 5 (21.73%) of the 23 adenocarcinomas and were associated, where known, with smoking habits. We never found EGFR alterations in tumors with Kras mutations.
Conclusions:
Our results provide oncologists with a highly accurate laboratory method to identify biological predictors of the efficacy of different therapies, and they may have an important impact on clinical practice. This method may be particularly useful in patients with advanced/metastatic NSCLC.
Insights
Analyzing cytologic specimens for epidermal growth factor receptor (EGFR) and Kras mutations in non-small cell lung cancer (NSCLC) can guide targeted therapy. This molecular analysis is effective even with limited tissue samples from advanced NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Somatic mutations in EGFR are linked to EGFR tyrosine kinase inhibitor (TKI) sensitivity in lung adenocarcinomas.
- Kras mutations are associated with resistance to targeted therapies in non-small cell lung cancer (NSCLC).
- Mutational analysis of tumor characteristics aids in personalizing treatment strategies for NSCLC.
Purpose of the Study:
- To evaluate the adequacy of archived cytologic specimens for detecting EGFR and Kras mutations in advanced NSCLC.
- To determine the frequency of EGFR and Kras mutations in lung adenocarcinomas.
- To explore associations between these mutations and clinical factors like gender and smoking history.
Main Methods:
- Archived cytologic specimens from 23 advanced/metastatic lung adenocarcinomas were analyzed.
- Mutations in EGFR exons 18-21 and Kras exon 2 were detected using molecular analysis.
- Statistical methods were used to assess associations between mutations and clinical characteristics.
Main Results:
- Cytologic specimens are suitable for EGFR and Kras mutation analysis.
- EGFR TK domain mutations were identified in 13.04% of cases, correlating with female gender and non-smoking history.
- Kras mutations were found in 21.73% of cases, associated with smoking history; no EGFR alterations were found in tumors with Kras mutations.
Conclusions:
- A precise laboratory method exists for identifying biomarkers that predict targeted therapy efficacy in NSCLC.
- This molecular testing approach is particularly valuable for patients with advanced or metastatic NSCLC.
- The findings have significant implications for tailoring treatment decisions in clinical practice.
